small molecule

XDEMVY

LOTILANER

Loss of exclusivityDecember 2038latest FDA-listed patent expiry

CompanyTarsus Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	XDEMVY
Active ingredient	LOTILANER
Strength	0.25%
Dosage form	SOLUTION/DROPS
Route	OPHTHALMIC
Modality	Small molecule
FDA approval	July 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
11690827	December 2038	use U-3674
11690826	December 2038	use U-3674
11197847	December 2038	use U-3674
10835517	December 2038	use U-3674
12171750	December 2038	use U-3674
11752137	December 2038	product
12213964	December 2038	product
12364685	December 2038	product
8383659	January 2030	substance, product

Regulatory exclusivity

Code	Expires
NCE	July 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.